Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.

199775 citationsJournal Article

Authors

G.J. Creemers · Rotterdam University of Applied Sciences

C J Gerrits

Abstract

The DLT in this phase I study for chronic oral topotecan for 21 days was diarrhea. The recommended dose for phase II studies is 0.5 mg/m2 twice daily.

Topics & Keywords

Cancer therapeutics and mechanisms Neuroblastoma Research and Treatments Lung Cancer Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 15, Issue 3, pp. 1087-1093

DOI: 10.1200/jco.1997.15.3.1087

Field-Weighted Citation Impact: 3.60